HighTide Therapeutics

HighTide Therapeutics ( develops multifunctional therapies targeting residual risks in cardiovascular-kidney-metabolic (CKM) diseases.

[HighTide Therapeutics @HighTideThera]

HighTide Therapeutics Announces Publication of Phase III Results of HTD1801 in NEJM Evidence

HTD1801 delivers sustained glycemic control and broad benefits across the CKM spectrum, supported by favorable long-term safety.

[HighTide Therapeutics @HighTideThera]

ADA 2026 l HighTide Therapeutics Presents Data from Three HTD1801 Studies, Highlighting Foundational Therapeutic Potential in CKM Diseases

✅ Long-term extension data,
✅ Head-to-head Phase III results,
✅ Combination data in weight management

#HTD1801 #ADA2026 #CKMDiseases

[HighTide Therapeutics @HighTideThera]

ERA2026 l HighTide Therapeutics Presents New Findings Supporting HTD1801's Renoprotective Potential in Oral Presentation

Targeting the AMPK-NLRP3 axis, HTD1801 continues to show promising renoprotective potential in CKD and other renal diseases.

[HighTide Therapeutics @HighTideThera]

Looking ahead to the 63rd Congress of the European Renal Association (ERA 2026)

HighTide Therapeutics will present new findings on HTD1801 and its renoprotective potential.

📍Glasgow, UK
🗓 June 4, 2026
🎤Oral Presentation #2243

#ERA2026 #KidneyResearch #HTD1801

[HighTide Therapeutics @HighTideThera]

HighTide Therapeutics Announces NDA Acceptance for HTD1801

Highlights:
• 3 Phase III trials met endpoints
• Benefits across the CKM spectrum
• First-in-class New Molecular Entity

#HTD1801 #Biopharma #ClinicalTrials #DrugDevelopment #Diabetes

🔗https://t.co/UJWYkV9ACC

[HighTide Therapeutics @HighTideThera]

HighTide Therapeutics (https://t.co/IcH9cL2con) names Dr. Filip Surmont as Chief Medical Officer, strengthening its global clinical development and CKM disease portfolio.

#biotech #PharmaLeadership #clinicaldevelopment #HealthcareInnovation #PharmaNews #healthcare

[HighTide Therapeutics @HighTideThera]

🌐HighTide Therapeutics Presents Renal Data for HTD1801, Reinforcing Its Potential as a Foundational CKM Therapy at CVCT Forum.

Follow us for more updates.

#HightideTherapeutics #CVCT2025 #HTD1801 #CKM #KidneyHealth #Cardiometabolic #ClinicalResearch

[HighTide Therapeutics @HighTideThera]

Post

🌐HighTide will present multifaceted CKM evidence for HTD1801 at CVCT 2025!

🎤Late-Breaking Oral Presentation
Dec 9 | 08:30–10:30 ET

📌 Poster Presentation
Dec 8–10

📍 Washington DC, US

We look forward to sharing more insights from the event.

@HighTideThera #HTD1801

[HighTide Therapeutics @HighTideThera]

HighTide Therapeutics’ HTD1801 Achieves Greater HbA1c Reduction & Superior Cardiometabolic Marker Improvement Versus Dapagliflozin in Phase III Head-to-Head Trial
✔ Greater HbA1c reduction
✔ Superior cardiometabolic improvements versus dapagliflozin
✔ Favorable safety profile

[HighTide Therapeutics @HighTideThera]

🚨 Late-Breaking @ASNKidney 2025!

New data from @HighTideThera show #HTD1801 improves eGFR in patients with mild renal impairment — the first clinical evidence of potential kidney benefit in early #CKD.

📍Poster #TH-PO1190 | 🗓️Nov 6 | 10AM–12PM

[HighTide Therapeutics @HighTideThera]

📣 Late-Breaking at #ASN2025!

Excited to share new evidence of kidney benefit with #HTD1801 in patients with mild renal impairment.

📅 Nov 6 | 🕙 10AM–12PM (CT)
📍 Houston, TX
🧪 Poster TH-PO1190

Join us at #KidneyWeek as we advance innovation in #renalhealth.

[HighTide Therapeutics @HighTideThera]

Major Milestone for HighTide Therapeutics
Breakthrough in #Type2Diabetes!

HighTide has completed two Phase 3 trials — SYMPHONY-1 & SYMPHONY-2 — for #HTD1801, a first-in-class anti-inflammatory metabolic modulator, showing durable 52-week efficacy & multi-system benefits.

[HighTide Therapeutics @HighTideThera]

Could adding a dual-action metabolic modulator to #obesity medication drive enhanced weight loss & glycemic control, with added cardiovascular benefits? Don't miss Leigh's presentation at the @HansonWade Obesity & Weight Loss Drug Development Summit today.

[HighTide Therapeutics @HighTideThera]

HTD1801 continues to show promise as a treatment for complex metabolic diseases, meeting its Phase 3 primary endpoints as a monotherapy for Type 2 #diabetes. See the results presented in a late-breaking abstract at #ADA2025: https://t.co/OgnQnI8olQ

[HighTide Therapeutics @HighTideThera]

We're excited to be in Amsterdam for #EASLCongress! Stop by our poster tomorrow to see promising new preclinical data on Rimtoregtide (HTD4010), an immunomodulatory peptide that may offer new hope in treating #hepatitis & other acute liver conditions

📌 FRI-141 | 8:30 am

[HighTide Therapeutics @HighTideThera]

Presented today at #DDW2025: Preclinical results for rimtoregtide (HTD4010) show protective effects in an acute #pancreatitis model in rats, with potential implications in other acute inflammatory conditions. Learn more: https://t.co/bU8H1Tkh2y

[HighTide Therapeutics @HighTideThera]

HighTide will present three exciting datasets at #EASLCongress, including:

💊Phase 2 post-hoc analyses for HTD1801 in #MASH + #T2DM
💊Preclinical data on HTD4010 in acute liver failure

🔗 Details here: https://t.co/eLJOHkhHgM